7:33 PM
 | 
Sep 11, 2007
 |  BC Extra  |  Company News

Basilea submits alitretinoin MAAs

Basilea (SWX:BSLN) submitted MAAs in undisclosed European countries under the decentralized procedure for oral alitretinoin to treat severe...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >